TY - JOUR T1 - Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 JF - N Engl J Med Y1 - 2015 A1 - Naggie, S. A1 - Cooper, C. A1 - Saag, M. A1 - Workowski, K. A1 - P J Ruane A1 - Towner, W.J. A1 - Marks, K. A1 - Luetkemeyer, A. A1 - Baden, R.P. A1 - Sax, P.E. A1 - E J Gane A1 - Santana-Bagur, J. A1 - Stamm, L.M. A1 - Yang, J.C. A1 - German, P. A1 - Dvory-Sobol, H. A1 - Ni, L. A1 - Pang, P.S. A1 - J G McHutchison A1 - Stedman, C.A. A1 - Morales-Ramirez, J.O. A1 - Brau, N. A1 - Jayaweera, D. A1 - Colson, A.E. A1 - Tebas, P. A1 - Wong, D.K. A1 - D. Dieterich A1 - M S Sulkowski A1 - ION-4 Investigators KW - Alabama KW - Antiretroviral KW - Baltimore KW - Boston KW - California KW - Canada KW - Cities KW - Diarrhea KW - efavirenz KW - emtricitabine KW - England KW - Fatigue KW - Genotype KW - genotype 1 KW - HCV KW - Headache KW - Health KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hiv-1 KW - Human KW - Israel KW - Liver KW - Los Angeles KW - Medicine KW - methods KW - New England KW - New York KW - New Zealand KW - NS5A inhibitor KW - Patients KW - Philadelphia KW - Puerto Rico KW - raltegravir KW - Research KW - rilpivirine KW - San Francisco KW - sofosbuvir KW - sustained virologic response KW - tenofovir KW - therapy KW - treatment KW - Universities KW - Veterans VL - 373 SP - 705-713 IS - 8 ER -